Viking Therapeutics, Inc.
Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its pipeline includes oral and injectable drug candidates such as VK2735, VK2809, VK0214, and VK5211, with research and development centered in San Diego, California.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDual GLP-1/GIP receptor agonist being developed in oral and subcutaneous forms for obesity and related metabolic disorders.
Oral thyroid hormone receptor beta agonist being developed for NASH/MASH and other metabolic liver disorders.
Investigational program targeting metabolic and endocrine disease pathways.
Additional preclinical or clinical-stage therapeutic program within the company’s pipeline.
Research, clinical trial execution, and manufacturing preparation across the pipeline.
Customers
Viking does not yet sell approved products; its near-term counterparties are clinical trial participants, investigators, CROs, manufacturers, and potential licensing or commercialization partners. If approved, its eventual customers would be physicians, patients, and healthcare payors in obesity and metabolic disease markets.
Patients, investigators, CROs, and trial sites that support testing of VK2735, VK2809, and other programs.
Third-party API and fill/finish providers that produce clinical and future commercial supply.
Biopharma partners that may help fund development, market products, or provide commercial infrastructure.
Patients who would use approved therapies for obesity, NASH/MASH, and related disorders.
Physicians and payors that would determine adoption, access, and reimbursement after approval.
Strategy
Viking’s strategy is to advance a focused pipeline of metabolic and endocrine drug candidates through clinical development, with VK2735 as the lead program. It is also building manufacturing capacity and optionality so that, if approved, it can support larger-scale supply and potential commercialization or partnering.
The lead obesity program is the main value driver and the most advanced asset in the pipeline.
Multiple formulations can broaden patient access and improve commercial flexibility if approved.
Dedicated API and fill/finish capacity is needed to support late-stage trials and potential launch supply.
Additional assets reduce single-asset dependence and create future partnering or development options.
Geography
Viking is headquartered in San Diego, California and conducts its research and development from the United States. Its business is primarily U.S.-based, while clinical development, manufacturing, and any future commercialization could involve third-party partners and trial sites in multiple countries.
Risks
Viking is a clinical-stage company with no approved products, so its value depends heavily on clinical, regulatory, and manufacturing execution. It also relies on licensed technology and third-party partners, which creates concentration risk if trials fail, approvals are delayed, or supply arrangements do not perform as expected.
- Clinical development failure or delayImpact: CriticalLikelihood: Medium
The company’s pipeline is still in development, so negative trial results or slow enrollment can materially reduce value.
Exposure - Financing riskImpact: HighLikelihood: High
The company expects continued losses and may need additional capital to complete development and commercialization.
Exposure - Dependence on licensed technology from LigandImpact: HighLikelihood: Medium
Loss or restriction of the master license agreement would impair the ability to develop current and future candidates.
Exposure: Core platform and pipeline
- Manufacturing and supply execution riskImpact: HighLikelihood: Medium
Late-stage trials and future launch require reliable API, fill/finish, and device supply at scale.
Exposure: CordenPharma agreements and future commercial supply
- Commercial adoption and reimbursement riskImpact: MediumLikelihood: Medium
Even if approved, uptake depends on efficacy, safety, convenience, and payor coverage in competitive obesity markets.
Exposure: Future marketed products
Accounting
Judgemental itemsClinical trial, CRO, and manufacturing costs are estimated based on progress and invoices, affecting period-to-period expense timing.
Impact: R&D expense and accrued liabilities
Equity awards and ESPP accounting can materially affect operating expenses for a small clinical-stage company.
Impact: G&A and R&D expense
Prepayments to CordenPharma are credited against future orders and affect cash flow and balance sheet presentation.
Impact: Cash, prepaid assets, and future supply costs
Loss carryforwards and other deferred tax assets may not be realizable without future taxable income.
Impact: Income tax provision and balance sheet valuation allowance
Similar listed companies
Publicly listed companies with a comparable business focus.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
vTv Therapeutics Inc.
VTVT · Pharmaceutical Preparations
Skye Bioscience, Inc.
SKYE · Pharmaceutical Preparations
MetaVia Inc.
MTVA · Pharmaceutical Preparations
Bicycle Therapeutics plc
BCYC · Pharmaceutical Preparations
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company built around its proprietary Bicycle platform, which is used to design short synthetic…
Camber Energy, Inc.
CEIN · Crude Petroleum & Natural Gas
Last updated: 24/09/2026